# Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma

> **NCT04829097** · PHASE3 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 80 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **COMBINATION_PRODUCT:** Temozolomide

## Key facts

- **NCT ID:** NCT04829097
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2021-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04829097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04829097, "Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04829097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*